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M
any large randomised trials 
have provided an abundance 
of high-quality evidence for 
the beneﬁ  ts of managing two major 
cardiovascular risk factors—high 
blood pressure and high cholesterol. 
National guidelines in turn distil this 
evidence and aid clinicians in making 
decisions about how best to manage 
their patients’ care. However, despite 
the existence of clear evidence-based 
guidelines, many patients at risk of 
cardiovascular disease who should 
be receiving treatment are not, while 
many others who are on treatment are 
not receiving treatment in line with 
recommendations. A paper in last 
month’s PLoS Medicine and another in 
this issue of the journal illustrate such 
“treatment gaps”.
Two New Studies on the 
“Treatment Gap”
One of the papers, by Ma et al. [1], 
uses United States national survey data 
collected over a ten-year period to 
obtain estimates of statin use among 
patients categorized by their risk of 
coronary heart disease and presence/
absence of hyperlipidaemia. Not 
surprisingly, the results show a more 
than 2-fold increase in the proportion 
of patients with hyperlipidaemia 
treated with lipid lowering agents 
between 1992 and 2002— statins 
accounting for most of this increase. 
However, even at the point of highest 
treatment uptake, only around half 
of patients with hyperlipidaemia were 
receiving treatment. 
Even more striking are the results 
for the use of statins in patients 
categorized by their cardiovascular 
risk. Among patients at high risk, the 
absolute maximum proportion of 
individuals receiving treatment at the 
end of the ten-year review period (i.e., 
in 2002) was only 19%. Additional 
analyses suggest that lower statin 
use in at-risk patients was associated 
with younger age, female gender, 
African-American background, and 
care by non-cardiologists. The authors 
appropriately conclude that statins 
remain underused —particularly 
among patients who have normal lipid 
levels but who are otherwise at high 
cardiovascular risk [2]. 
A similar evidence–practice gap, this 
time for blood pressure, is highlighted 
in the other article, by Morgan et al. 
[3]. In this paper, data from public, 
medical, hospital, and pharmaceutical 
programs in British Columbia are 
used to determine trends in the 
use of thiazide diuretics compared 
with other, more costly agents as a 
ﬁ  rst-line treatment to lower blood 
pressure among older, newly treated 
patients with hypertension. The results 
show that only around one-third of 
patients received thiazide diuretics. 
Furthermore, even in the absence 
of certain comorbidities—such as 
diabetes, which might inﬂ  uence a 
clinician to choose an alternative 
agent—thiazides were used in no more 
than 45% of older eligible patients. 
Compared with newer agents such 
as angiotensin receptor blockers 
and calcium antagonists, which cost 
upwards of US$1.00/day, thiazides 
remain the cheapest blood pressure 
lowering agents, costing less than 
$0.01/day. The authors reasonably 
argue that as long as thiazides remain 
at least equivalent to other blood 
pressure lowering agents in terms of 
reducing cardiovascular mortality and 
morbidity [4], their preferential use as 
a ﬁ  rst-line agent can be justiﬁ  ed on the 
basis of their low cost. 
Narrowing the Gap
Why do such gaps between evidence 
and practice exist? In 2002, around 
800 primary care physicians in ﬁ  ve 
European countries were surveyed 
to assess the acceptance and or 
implementation of treatment 
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Table 1. The Reassessing European Attitudes about Cardiovascular Treatment Survey: 
Most Commonly Cited Barriers to Implementation of Coronary Heart Disease Guidelines
Country
Number of 
Physicians 
in Survey
Number (Percent) of Physicians Who Cited Barrier
Lack of 
Time
(Prescribing) 
Cost
Patient 
Compliance
Too Many 
Guidelines
Around
Not Fully 
Aware of 
Guidelines
France 152   13 (9)    26 (17)    52 (34)    5 (3)    13 (9)
Germany 152   30 (20)    80 (53)    31 (20)    21 (14)    11 (7)
UK 150   86 (57)    85 (57)    27 (18)    15 (10)    11 (7)
Italy 150   63 (42)    13 (9)    4 (3)    30 (20)    9 (6)
Sweden  150   98 (65)    25 (17)    15 (10)    5 (3)    30 (20)
Total 754  290 (38)  229 (30)  129 (17)    76 (10)    74 (10)
Data from [5].
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guidelines for high cholesterol 
and coronary heart disease (the 
Reassessing European Attitudes about 
Cardiovascular Treatment survey) 
[5]. Although most (89%) of those 
interviewed acknowledged the need 
for formal guidelines, and a similar 
proportion agreed with the content 
of current guidelines, only 18% of 
physicians believed that guidelines were 
being implemented to a major extent, 
indicating a problem with either their 
understanding or implementation. The 
barriers to implementation that were 
most commonly cited by physicians in 
the survey are shown in Table 1.
Perhaps the two most important 
means by which improved use of 
treatment guidelines can be achieved 
are (1) improving the understanding 
of the basic concepts that underpin 
them and (2) reducing the number 
and complexity of the main messages. 
In terms of addressing the ﬁ  rst of these, 
an understanding of the concept of 
“absolute risk”—the probability of a 
patient developing a cardiovascular 
event over a speciﬁ  ed time period—is 
crucial. 
An absolute risk approach 
to cardiovascular prevention 
acknowledges that the presence 
of small or moderate elevations of 
multiple risk factors often confer 
greater risk of cardiovascular disease 
than an extreme elevation of a 
single risk factor. Furthermore, the 
nature of the association between 
blood pressure, cholesterol, and 
cardiovascular disease implies that a 
given reduction in the level of the risk 
factor, regardless of baseline level, will 
reduce cardiovascular risk by a constant 
proportion. Therefore, the goal of 
blood pressure lowering and lipid 
lowering is not to “normalize” levels but 
to reduce them as much as possible, 
and this means targeting everyone 
at high risk as determined by age or 
known cardiovascular disease rather 
than by the level of the risk factors [6]. 
This approach (“the lower, the better”) 
to both blood pressure and cholesterol 
management in high-risk individuals 
has been supported by recent meta-
analyses and large trials [7,8]. 
Adopting an absolute-risk-based 
approach requires a paradigm shift 
and challenges the way doctors have 
traditionally made treatment decisions 
based on single risk factor levels. 
Although there is some evidence that 
clinical practice is conforming to the 
notion of risk stratiﬁ  cation, other 
studies suggest that a large proportion 
of clinicians, particularly those in 
primary care, still do not use risk charts 
[5]. While it is acknowledged that 
the absolute risk approach has some 
limitations, integration of this approach 
into clinical care will be the key to 
future major gains in the prevention of 
cardiovascular disease.  
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